Last reviewed · How we verify

immunotherapy Staloral

Medical University of Silesia · FDA-approved active Small molecule

immunotherapy Staloral is a Sublingual immunotherapy (SLIT) Small molecule drug developed by Medical University of Silesia. It is currently FDA-approved for Allergic rhinitis and/or allergic asthma caused by grass pollen allergens, Allergic rhinitis and/or allergic asthma caused by tree pollen allergens.

Staloral is a sublingual immunotherapy that desensitizes the immune system to allergens by inducing immune tolerance through repeated exposure to gradually increasing allergen doses.

Staloral is a sublingual immunotherapy that desensitizes the immune system to allergens by inducing immune tolerance through repeated exposure to gradually increasing allergen doses. Used for Allergic rhinitis and/or allergic asthma caused by grass pollen allergens, Allergic rhinitis and/or allergic asthma caused by tree pollen allergens.

At a glance

Generic nameimmunotherapy Staloral
SponsorMedical University of Silesia
Drug classSublingual immunotherapy (SLIT)
ModalitySmall molecule
Therapeutic areaImmunology / Allergy
PhaseFDA-approved

Mechanism of action

Staloral works by administering small, increasing doses of allergen extract under the tongue, which promotes a shift from Th2-mediated allergic responses to Th1/Treg-mediated tolerance. This sublingual immunotherapy (SLIT) approach allows for gradual immune system adaptation to the allergen, reducing allergic symptoms and the need for symptomatic medications over time.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about immunotherapy Staloral

What is immunotherapy Staloral?

immunotherapy Staloral is a Sublingual immunotherapy (SLIT) drug developed by Medical University of Silesia, indicated for Allergic rhinitis and/or allergic asthma caused by grass pollen allergens, Allergic rhinitis and/or allergic asthma caused by tree pollen allergens.

How does immunotherapy Staloral work?

Staloral is a sublingual immunotherapy that desensitizes the immune system to allergens by inducing immune tolerance through repeated exposure to gradually increasing allergen doses.

What is immunotherapy Staloral used for?

immunotherapy Staloral is indicated for Allergic rhinitis and/or allergic asthma caused by grass pollen allergens, Allergic rhinitis and/or allergic asthma caused by tree pollen allergens.

Who makes immunotherapy Staloral?

immunotherapy Staloral is developed and marketed by Medical University of Silesia (see full Medical University of Silesia pipeline at /company/medical-university-of-silesia).

What drug class is immunotherapy Staloral in?

immunotherapy Staloral belongs to the Sublingual immunotherapy (SLIT) class. See all Sublingual immunotherapy (SLIT) drugs at /class/sublingual-immunotherapy-slit.

What development phase is immunotherapy Staloral in?

immunotherapy Staloral is FDA-approved (marketed).

What are the side effects of immunotherapy Staloral?

Common side effects of immunotherapy Staloral include Oral pruritus, Throat irritation, Mouth edema, Ear pruritus, Gastrointestinal symptoms.

Related